Protagonist Therapeutics Inc expected to post a loss of 93  cents a share - Earnings Preview

Protagonist Therapeutics

29/07/2022 12:16

* Protagonist Therapeutics Inc  PTGX.OQ   PTGX.O  is
expected
to show a fall in quarterly revenue when it reports  results on
August 2 (estimated). 
    * The Newark California California-based  company is
expected to
report  a 83.1% decrease in revenue to $383.33 thousand from
$2.27 million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Protagonist
Therapeutics
Inc is for a loss of 93 cents per share. For the same quarter
last year, the company reported a loss of 69 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Protagonist
Therapeutics Inc is $40​, above​ its last closing price
of $10.25. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.58       -0.63      -0.43     Beat    31.6
 Dec. 31 2022  -0.81       -0.78      -0.77     Beat    1.6
 Sep. 30 2021  -0.69       -0.67      -0.70     Missed  -4.5​
 Jun. 30 2021  -0.54       -0.55      -0.69     Missed  -26.1
 ​​Mar.        -0.56       -0.57      -0.54     Beat    4.9
 31 2021                                                
 Dec. 31 2020  -0.50       -0.48      -0.48     Met     -0.4​
 Sep. 30 2020  -0.61       -0.61      -0.21     Beat    65.7
 Jun. 30 2020  -0.58       -0.59      -0.61     Missed  -2.5
 This summary was machine generated July 29 at 11:16 GMT.  All
figures in US dollars  unless otherwise stated